

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

**APPLICATION NUMBER
21-344**

Medical/Statistical Review(s)

CLINICAL REVIEW

NDA 21-344:
New Drug Application
Fulvestrant (FASLODEX™)

**FDA Center for Drug Evaluation and
Research**

Division of Oncology Drug Products

**Combined Medical/Statistical
NDA Review**

Medical Reviewer: Peter Bross, MD

Medical Team Leader: Grant Williams, MD

Statistical Reviewer: Peiling Yang, Ph.D

Statistical Team Leader: Gang Chen, Ph.D

Table of Contents

1.	Executive Summary.....	5
a.	Recommendations	5
i.	Recommendation on Approvability	5
ii.	Recommendation on Phase 4 Studies and/or Risk Management Steps	5
b.	Summary of Clinical Findings	6
i.	Brief Overview of Clinical Program	6
ii.	Efficacy	7
iii.	Safety.....	8
iv.	Dosing	9
v.	Special Populations	9
2.	Clinical Review	9
a.	Introduction and Background	9
i.	Drug Established and Proposed Trade Name, Drug Class, Applicant’s Proposed Indication(s), Dose, Regimens, Age Groups	9
ii.	Drug Chemical Structure.....	10
iii.	State of Armamentarium for Indication(s).....	10
b.	Important Milestones in Product Development	16
c.	Important Issues with Pharmacologically Related Agents.....	18
d.	Clinically Relevant Findings From Chemistry, Animal Pharmacology and Toxicology, Microbiology, Biopharmaceutics, Statistics and/or Other Consultant Reviews	18
i.	Pharmacology/Toxicology	18
e.	Human Pharmacokinetics and Pharmacodynamics	21
i.	Pharmacokinetics	21

CLINICAL REVIEW

ii.	Pharmacodynamics.....	23
f.	IV. Description of Clinical Data and Sources.....	29
i.	Overall Data.....	29
ii.	Tables Listing the Clinical Trials.....	29
iii.	Literature Review.....	33
g.	Clinical Review Methods.....	34
i.	How the Review was Conducted.....	34
ii.	Overview of Materials Consulted in Review.....	34
iii.	Overview of Methods Used to Evaluate Data Quality and Integrity.....	34
iv.	Were Trials Conducted in Accordance with Accepted Ethical Standards.....	35
v.	Evaluation of Financial Disclosure.....	35
3.	Integrated Review of Efficacy.....	36
a.	Brief Statement of Conclusions.....	36
b.	General Approach to Review of the Efficacy of the Drug.....	37
i.	Phase 2 studies of efficacy.....	37
ii.	Phase 3 studies reviewed in detail.....	38
iii.	Ongoing studies in first line indication.....	39
c.	Detailed Review of Trials by Indication.....	39
i.	Proposed indication.....	39
ii.	Overview of the clinical trial program.....	40
iii.	Phase 3 clinical trials.....	41
iv.	Efficacy assessments.....	45
v.	Statistical plan.....	49
vi.	Study conduct.....	52
vii.	Combined Results of Randomized Trials.....	55

CLINICAL REVIEW

viii.	Efficacy results by trial: Trial #20 (European open label)	60
ix.	Efficacy results by trial: Trial #21 (North American - double blind double dummy)	72
x.	Preliminary Results of trial #0025 in first line indication	85
xi.	Overall Efficacy Conclusions.....	87
d.	Integrated Review of Safety	90
i.	Brief Statement of Conclusions	90
ii.	Description of Patient Exposure.....	90
iii.	Methods and Specific Findings of Safety Review	92
iv.	Adequacy of Safety Testing	96
v.	Summary of Critical Safety Findings and Limitations of Data.....	97
e.	Dosing, Regimen, and Administration Issues	97
f.	Use in Special Populations.....	98
i.	Evaluation of Applicant's Gender Effects Analyses and Adequacy of Investigation.....	98
ii.	Evaluation of Evidence for Age, Race, or Ethnicity Effects on Safety or Efficacy	98
iii.	Evaluation of Pediatric Program	98
iv.	Comments on Data Available or Needed in Other Populations.....	99
g.	Conclusions and Recommendations	99
i.	Conclusions	99
ii.	Dosing	100
iii.	Tradename issues	100
iv.	Recommendations	100

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.